This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Second Look: Discussing the Phase 3 clinical trial of Otsuka and Lundbeck’s Rexulti (brexpiprazole) in patients with agitation from Alzheimer's dementia released at the 2022 Alzheimer's Association International Conference

Ticker(s): OTSKY

Who's the expert?

Institution: Amwell, Northside Hospital

  • Board certified internist with a background in ER, pathology, hospital, and critical care
  • Manages about 25-50 patients monthly with NASH
  • Familiar with the potential treatments for NASH including Ozempic and have used it off label for years to ameliorate the condition

Interview Goal
To discuss the standard of care and the potential of Otsuka and Lundbeck’s drug Rexulti (brexpiprazole) for agitation associated with Alzheimer’s dementia (AAD) including the Phase 3 clinical trial of brexpiprazole in patients with Alzheimer's dementia presented at the 2022 Alzheimer's Association International Conference.

Do you want answers to these questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.